Literature DB >> 11263499

Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.

M D Ledesma1, J S Da Silva, K Crassaerts, A Delacourte, B De Strooper, C G Dotti.   

Abstract

The proteolytic processing of amyloid precursor protein (APP) has been linked to sphingolipid-cholesterol microdomains (rafts). However, the raft proteases that may be involved in APP cleavage have not yet been identified. In this work we present evidence that the protease plasmin is restricted to rafts of cultured hippocampal neurons. We also show that plasmin increases the processing of human APP preferentially at the alpha-cleavage site, and efficiently degrades secreted amyloidogenic and non-amyloidogenic APP fragments. These results suggest that brain plasmin plays a preventive role in APP amyloidogenesis. Consistently, we show that brain tissue from Alzheimer's disease patients contains reduced levels of plasmin, implying that plasmin downregulation may cause amyloid plaque deposition accompanying sporadic Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11263499      PMCID: PMC1083779          DOI: 10.1093/embo-reports/kvd107

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  29 in total

1.  Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein.

Authors:  H Koike; S Tomioka; H Sorimachi; T C Saido; K Maruyama; A Okuyama; A Fujisawa-Sehara; S Ohno; K Suzuki; S Ishiura
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

2.  Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients.

Authors:  K Sennvik; J Fastbom; M Blomberg; L O Wahlund; B Winblad; E Benedikz
Journal:  Neurosci Lett       Date:  2000-01-14       Impact factor: 3.046

Review 3.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

4.  Differential specificities of the thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors.

Authors:  M J Weinstein; R F Doolittle
Journal:  Biochim Biophys Acta       Date:  1972-02-28

Review 5.  Structural biochemistry and activation of matrix metalloproteases.

Authors:  D E Kleiner; W G Stetler-Stevenson
Journal:  Curr Opin Cell Biol       Date:  1993-10       Impact factor: 8.382

6.  Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these fibrinolytic components to cells.

Authors:  L A Miles; C M Dahlberg; E G Levin; E F Plow
Journal:  Biochemistry       Date:  1989-11-28       Impact factor: 3.162

7.  The plasmin system is induced by and degrades amyloid-beta aggregates.

Authors:  H M Tucker; M Kihiko; J N Caldwell; S Wright; T Kawarabayashi; D Price; D Walker; S Scheff; J P McGillis; R E Rydel; S Estus
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

8.  Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments.

Authors:  C Haass; E H Koo; A Mellon; A Y Hung; D J Selkoe
Journal:  Nature       Date:  1992-06-11       Impact factor: 49.962

Review 9.  The cell biology of the plasminogen system.

Authors:  E F Plow; T Herren; A Redlitz; L A Miles; J L Hoover-Plow
Journal:  FASEB J       Date:  1995-07       Impact factor: 5.191

Review 10.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

View more
  73 in total

1.  Proteolysis in Alzheimer's disease. Can plasmin tip the balance?

Authors:  G Periz; M E Fortini
Journal:  EMBO Rep       Date:  2000-12       Impact factor: 8.807

2.  Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury.

Authors:  A W Harrington; B Leiner; C Blechschmitt; J C Arevalo; R Lee; K Mörl; M Meyer; B L Hempstead; S O Yoon; K M Giehl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-16       Impact factor: 11.205

3.  Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.

Authors:  Manel G Medina; Maria Dolores Ledesma; Jorge E Domínguez; Miguel Medina; Delia Zafra; Francesc Alameda; Carlos G Dotti; Pilar Navarro
Journal:  EMBO J       Date:  2005-04-21       Impact factor: 11.598

Review 4.  Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review.

Authors:  Toshio Ariga; Michael P McDonald; Robert K Yu
Journal:  J Lipid Res       Date:  2008-03-11       Impact factor: 5.922

5.  Reciprocal induction between α-synuclein and β-amyloid in adult rat neurons.

Authors:  Shohreh Majd; Fariba Chegini; Tim Chataway; Xin-Fu Zhou; Weiping Gai
Journal:  Neurotox Res       Date:  2012-05-19       Impact factor: 3.911

Review 6.  Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.

Authors:  Shu-Hui Xin; Lin Tan; Xipeng Cao; Jin-Tai Yu; Lan Tan
Journal:  Neurotox Res       Date:  2018-04-07       Impact factor: 3.911

7.  Gangliosides trigger inflammatory responses via TLR4 in brain glia.

Authors:  Ilo Jou; Jee Hoon Lee; Soo Young Park; Hee Jung Yoon; Eun-Hye Joe; Eun Jung Park
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 8.  Hemostasis components in cerebral amyloid angiopathy and Alzheimer's disease.

Authors:  Nicole Ziliotto; Francesco Bernardi; Fabrizio Piazza
Journal:  Neurol Sci       Date:  2021-05-27       Impact factor: 3.307

9.  Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro.

Authors:  Mei-Chen Liao; William E Van Nostrand
Journal:  Biochemistry       Date:  2010-02-16       Impact factor: 3.162

Review 10.  Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism.

Authors:  D Allan Butterfield; Miranda L Bader Lange
Journal:  J Neurochem       Date:  2009-09-23       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.